ArticleExtremophiles : life under extreme conditions2025
Actinomycetes from high altitude salt lake Tso-Kar of Ladakh offers bright prospects for antimycobacterial drug discovery especially for drug resistant mycobacteria.
Article in Extremophiles : life under extreme conditions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The rise of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (M. tb) has driven the search for new antimycobacterial agents. Our study focused on isolation and characterization of actinomycetes from the hypersaline Tso-Kar Salt lake in Ladakh, India, to explore their antibacterial potential. We isolated 145 bacterial isolates from various soil, salt and water samples and found 23 actinomycete isolates effective against Mycobacterium smegmatis through cross-streak screening. Molecular identification confirmed that these isolates belonged to 14 genera of actinomycetes. Out of 23 extracts from these isolates, 15 ethyl acetate organic extracts exhibited strong antimycobacterial activities against M. smegmatis, M. tb H37Ra, and M. tb H37Rv, with MIC values between 125 and 31.25 µg/mL. Importantly, all 15 extracts demonstrated bactericidal activities at their respective MICs against M. tb H37Rv. The other 8 extracts displayed comparatively weaker MIC and MBC ranging 500-250 µg/mL and 1000-500 µg/mL respectively. These extracts were equally effective against drug-resistant and drug-susceptible M. tb clinical isolates. Furthermore, they showed broad antibacterial activity against both gram-positive and gram-negative bacteria, with MICs ranging from 500 to 31.25 µg/mL. The GC-MS analysis of the potent extracts revealed that a wide range of compounds including Phenolics, Peptides, Ergot alkaloids and their derivates may have contributed to anti-mycobacterial activity. The genetic diversity and significant antimicrobial properties of these actinomycetes from extreme environments highlight their potential for developing new antituberculosis and general antibiotic agents, particularly against MDR infections.
Indexed as
Identifiers
40748406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.